Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.30 |
| ▸ | CES1 | P23141 | 2/20 | 0.30 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044365 | 0.72 | TSHR (0.42) | DAOTSHRNAPRTNPSR1EDNRA | |
| SCHEMBL3715233 | 0.68 | DAO (0.31) | DAOTSHRNAPRT | |
| SCHEMBL27498228 | 0.68 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL27327789 | 0.68 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL10111693 | 0.67 | — | — | |
| SCHEMBL29056026 | 0.67 | DAO (0.30) | DAOTSHRNAPRT | |
| SCHEMBL8846354 | 0.67 | — | — | |
| SCHEMBL28309978 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL28310644 | 0.64 | — | — | |
| SCHEMBL30676463 | 0.63 | NOS2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | DAO 1701/4885TSHR 1445/4885NAPRT 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.